{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Number of subjects with positive antibody titers"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Number of patients with negative antibody titers"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Blood samples were taken at baseline and weeks 4, 7, 10 and 13. Humoral immunity was assessed by measurement of antibodies to NY-ESO-1 or LAGE by enzyme-linked immunosorbent assay (ELISA). Positive results are reported as antibodies to NY-ESO-1- and/or LAGE-1-specific Total IgG (reciprocal titer).","groups":[{"description":"Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.","id":"OG000","title":"Ipilimumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects who entered the study.","reportingStatus":"POSTED","timeFrame":"up to 13 weeks","title":"Number of Subjects With NY-ESO-1 Specific Immunity as Measured by Antibody Response to NY-ESO-1 or LAGE-1","type":"SECONDARY","unitOfMeasure":"Participants"}